| Literature DB >> 34947934 |
Kristýna Hricová1, Magdaléna Röderová1, Petr Fryčák2, Volodymyr Pauk2, Ondřej Kurka2, Kristýna Mezerová1, Taťána Štosová1, Jan Bardoň1, David Milde2, Pavla Kučová1, Milan Kolář1.
Abstract
Due to the extensive use of antimicrobial agents in human and veterinary medicine, residues of various antimicrobials get into wastewater and, subsequently, surface water. On the one hand, a combination of processes in wastewater treatment plants aims to eliminate chemical and biological pollutants; on the other hand, this environment may create conditions suitable for the horizontal transfer of resistance genes and potential selection of antibiotic-resistant bacteria. Wastewater and surface water samples (Morava River) were analyzed to determine the concentrations of 10 antibiotics and identify those exceeding so-called predicted no-effect environmental concentrations (PNECs). This study revealed that residues of five of the tested antimicrobials, namely ampicillin, clindamycin, tetracycline, tigecycline and vancomycin, in wastewater samples exceeded the PNEC. Vancomycin concentrations were analyzed with respect to the detected strains of vancomycin-resistant enterococci (VRE), in which the presence of resistance genes, virulence factors and potential relationship were analyzed. VRE were detected in 16 wastewater samples (11%) and two surface water samples (6%). The PNEC of vancomycin was exceed in 16% of the samples. Since the detected VRE did not correlate with the vancomycin concentrations, no direct relationship was confirmed between the residues of this antimicrobials and the presence of the resistant strains.Entities:
Keywords: antimicrobial residues; vancomycin-resistant enterococci (VRE); wastewater
Year: 2021 PMID: 34947934 PMCID: PMC8706104 DOI: 10.3390/life11121403
Source DB: PubMed Journal: Life (Basel) ISSN: 2075-1729
Description of the sampling sites and identification of wastewater and surface water samples.
| Sample Identification | Acronym Explanation | Sample Type |
|---|---|---|
| MHO OUT1 | Military Hospital Olomouc—hospital sewer drain 1 | Raw sewage |
| MHO OUT2 | Military Hospital Olomouc—hospital sewer drain 2 | Raw sewage |
| MHO OUT3 | Military Hospital Olomouc—hospital sewer drain 3 | Raw sewage |
| UHO IN | University Hospital Olomouc—hospital wastewater treatment plant influent | Raw sewage |
| UHO OUT | University Hospital Olomouc—hospital wastewater treatment plant effluent | Treated sewage |
| MWWTP IN | Olomouc Municipal Wastewater Treatment Plant influent | Raw sewage |
| MWWTP OUT | Olomouc Municipal Wastewater Treatment Plant effluent | Treated sewage |
| SVI OUT | State Veterinary Institute wastewater treatment plant effluent | Treated sewage |
| SW IN | Surface water (Morava River)—before the Municipal Wastewater Treatment Plant influent | Surface water |
| SW OUT | Surface water (Morava River)—past the Municipal Wastewater Treatment Plant effluent | Surface water |
Nucleotide sequences of the primer sets used to amplify the pbp5 gene.
| Gene | Primer Name | Primer Sequence (5′ to 3′) | Amplicon Size (bp) |
|---|---|---|---|
|
| PBP5 6F | AACCGGTGATCTTCTTGCG | 756 |
| PBP5 6R | TTGATTTCCGCTGTACCAGT | ||
| PBP5 11F | GGGCTTAAATGGCAAAAAGA | 694 | |
| PBP5 11R | ATTGATAATTTTGGTTGAGGTAT |
Mean concentrations of antimicrobial residues detected in surface water and wastewater.
| Antibiotic | PNEC | Mean Concentration a,b (ng/L) | No. of Samples Exceeding PNEC c | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raw Waste-Water | Raw Waste-Water | Treated Waste-Water | Treated Wastewater | Surface Water | Raw Waste-Water | Raw Waste-Water | Treated Waste-Water | Treated Waste-Water | Surface Water | Total | ||
| nitrofurantoin | 64,000 | 9300 (2) |
|
|
|
|
|
|
|
|
|
|
| chloramphenicol | 8000 | 890 (69) | 160 (18) | 240 (8) | 10 (4) | 16 (4) |
|
|
|
|
|
|
| linezolid | 8000 | 1200 (22) | 48 (9) | 980 (16) | 10 (10) | 3 (5) |
|
|
|
|
|
|
| ampicillin | 250 | 48,000 (5) | 92 (1) | 38 (1) |
| 9 (1) | 4 |
|
|
|
| 4 |
| clindamycin | 1000 | 1500 (66) | 81 (16) | 1200 (17) | 38 (18) | 2 (9) | 16 |
| 6 |
|
| 22 |
| tetracycline | 1000 | 2700 (5) | 37 (2) | 120 (4) | 8 (1) | 7 (4) | 1 |
|
|
|
| 1 |
| tigecycline | 1000 | 800 (6) | 280 (1) |
| 950 (1) |
| 2 |
|
|
|
| 2 |
| vancomycin | 8000 | 4700 (58) | 140 (17) | 13,000 (18) | 45 (16) | 25 (6) | 16 |
| 13 |
|
| 29 |
| erythromycin | 1000 | 67 (35) | 36 (18) | 52 (10) | 12 (13) |
|
|
|
|
|
|
|
a In parentheses, the number of samples in which the analyte could be quantified (concentration > LOQ) is indicated; the mean concentrations were calculated using the number of samples with quantifiable concentrations. Total no. of samples: raw wastewater (hospital) = 90, raw wastewater (municipal) = 18, treated wastewater (hospital) = 18, treated wastewater (municipal) = 18 and surface water = 36. b “-” indicates that no numerical concentration value was available. c “-” indicates that no sample exceeded the PNEC. d Includes raw wastewater from the State Veterinary Institute in Olomouc.
All VRE obtained from the sampling sites.
| Laboratory Sample Identification | Sampling Site | Sample Type | Collection Date |
|---|---|---|---|
| WW1 | UHO IN | raw sewage | 10/2018 |
| WW2 | UHO IN | raw sewage | 11/2018 |
| WW3 | SW IN | surface water | 06/2019 |
| WW4 | UWWTP OUT | treated sewage | 06/2019 |
| WW5 | SW IN | surface water | 08/2019 |
| WW6 | MHO OUT3 | raw sewage | 08/2019 |
| WW7 | UWWTP OUT | treated sewage | 10/2019 |
| WW9 | UHO IN | raw sewage | 11/2019 |
| WW10 | UHO OUT | treated sewage | 11/2019 |
| WW11 | UHO OUT | treated sewage | 11/2019 |
| WW13 | UWWTP OUT | treated sewage | 01/2020 |
| WW14 | UWWTP OUT | treated sewage | 02/2020 |
| WW15 | UWWTP OUT | treated sewage | 02/2020 |
| WW16 | UHO OUT | treated sewage | 06/2020 |
| WW17 | UWWTP OUT | treated sewage | 06/2020 |
| WW18 | UWWTP OUT | treated sewage | 06/2020 |
| WW19 | UWWTP OUT | treated sewage | 07/2020 |
| WW20 | UWWTP OUT | treated sewage | 07/2020 |
Minimum inhibitory concentrations of the tested antibiotics in a series of 18 VRE.
| Laboratory Sample Identification | PEN | LNZ | AMP | TIG | CMP | TET | ERY | CLI | VAN | TEI | FUR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WW1 | 4 | 1.5 | 16 | 0.03 | 2 | 0.25 | 16 | 8 | 8 | 2 | 64 |
| WW2 | 4 | 2 | 16 | 0.03 | 2 | 16 | 16 | 8 | 32 | 32 | 512 |
| WW3 | 0.5 | 0.25 | 16 | 0.03 | 2 | 16 | 8 | 4 | 64 | 64 | 32 |
| WW4 | 2 | 1.5 | 16 | 0.03 | 1 | 16 | 8 | 4 | 64 | 32 | 32 |
| WW5 | 4 | 0.5 | 16 | 0.03 | 2 | 0.25 | 16 | 8 | 64 | 8 | 64 |
| WW6 | 4 | 0.25 | 16 | 0.03 | 2 | 16 | 16 | 8 | 64 | 8 | 64 |
| WW7 | 8 | 1 | 16 | 4 | 1 | 16 | 8 | 4 | 8 | 4 | 32 |
| WW9 | 2 | 1.5 | 16 | 0.5 | 2 | 0.5 | 4 | 4 | 32 | 2 | 64 |
| WW10 | 2 | 1.5 | 8 | 0.03 | 2 | 16 | 4 | 4 | 32 | 8 | 32 |
| WW11 | 2 | 1.5 | 16 | 0.03 | 2 | 0.5 | 4 | 4 | 8 | 0.5 | 32 |
| WW13 | 2 | 1 | 16 | 0.03 | 2 | 16 | 8 | 16 | 16 | 16 | 8 |
| WW14 | 2 | 1.5 | 16 | 0.03 | 2 | 16 | 8 | 2 | 16 | 16 | 16 |
| WW15 | 2 | 1.5 | 16 | 0.03 | 4 | 16 | 8 | 16 | 16 | 16 | 16 |
| WW16 | 2 | 2 | 16 | 0.03 | 4 | 16 | 8 | 4 | 16 | 32 | 256 |
| WW17 | 2 | 1 | 16 | 0.06 | 1 | 16 | 4 | 0.06 | 32 | 16 | 32 |
| WW18 | 2 | 0.03 | 16 | 0.03 | 4 | 0.5 | 8 | 4 | 16 | 8 | 256 |
| WW19 | 2 | 0.03 | 16 | 0.03 | 2 | 8 | 4 | 8 | 16 | 8 | 32 |
| WW20 | 2 | 0.03 | 16 | 0.03 | 4 | 0.25 | 4 | 8 | 64 | 8 | 64 |
Legend: values shown in mg/L; PEN—penicillin, LNZ—linezolid, AMP—ampicillin, TIG—tigecycline, CMP—chloramphenicol, TET—tetracycline, ERY—erythromycin, CLI—clindamycin, VAN—vancomycin, TEI—teicoplanin and FUR—nitrofurantoin.
Distribution of tetracycline and macrolide genes among the VRE isolates.
| No. of | Presence of Gene(s) | MIC Range (µg/mL) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| tet | tet | tet | tet | tet | tet | erm | erm | mef | ERY | CLI | TET | |
| 3 | - | + | + | - | - | - | - | + | - | 4–8 | 4–16 | 16 |
| 4 | - | + | + | - | - | - | - | - | - | 4–16 | 0.06–8 | 0.25–16 |
| 5 | - | - | + | - | - | - | - | + | - | 4–16 | 4–16 | 0.25–16 |
| 1 | - | - | + | - | - | - | - | - | - | 8 | 4 | 16 |
| 5 | - | - | - | - | - | - | - | + | - | 4–16 | 4–8 | 0.25–16 |
Legend: ERY—erythromycin, CLI—clindamycin and TET—tetracycline.
pbp5 allele polymorphisms in the C-terminal region of the VRE isolates.
| Amino Acid Changes at Position | MIC Range of Ampicillin (µg/mL) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | 461 |
| 470 | 471 |
| 487 |
| 497 |
|
| 581 |
| 595 | 622 |
| 631 | 634 | ||
| X84860 | Q | - | H | V | M | Q | N | F | A | E | I | V | E | E | E | G | N | - | |
| A | 11 | K | S | Q | V | A | Q | K | F | T | D | I | V | E | E | V | G | N | 16 |
| B | 6 | Q | S | Q | V | A | Q | K | F | T | D | I | V | E | E | V | G | N | 16 |
| C | 1 | Q | D | Q | V | A | Q | K | F | I | D | I | V | E | E | V | G | N | 8 |
Bold letters indicate amino acid positions potentially significant in beta-lactam resistance.
Figure 1Pulse-field gel electrophoresis dendrogram of 18 VRE E. faecium isolates.
Figure 2Detection of VRE in the UHO IN samples during the study. x-axis: vancomycin concentration in ng/L/y-axis: collection dates; arrow outline—VRE detection and sample identification; solid red arrow—VRE detection and VRE concentration exceeding the PNEC and sample identification; red horizontal line—the PNEC for vancomycin (8000 ng/L).
Figure 3Detection of VRE in the UHO OUT samples during the study. x-axis: vancomycin concentration in ng/L/y-axis: collection dates; arrow outline—VRE detection and sample identification; solid red arrow—VRE detection and VRE concentration exceeding the PNEC and sample identification; red horizontal line—the PNEC for vancomycin (8000 ng/L).
Figure 4Detection of VRE in the MHO OUT3 samples during the study. x-axis: vancomycin concentration in ng/L/y-axis: collection dates; arrow outline—VRE detection and sample identification; solid red arrow—VRE detection and VRE concentration exceeding the PNEC and sample identification; red horizontal line—the PNEC for vancomycin (8000 ng/L).
Figure 5Detection of VRE in the surface water (SW IN) samples during the study. x-axis: vancomycin concentration in ng/L/y-axis: collection dates; arrow outline—VRE detection and sample identification; solid red arrow—VRE detection and VRE concentration exceeding the PNEC and sample identification; red horizontal line—the PNEC for vancomycin (8000 ng/L).
Figure 6Detection of VRE in the MWWTP OUT samples during the study. x-axis: vancomycin concentration in ng/L/y-axis: collection dates; arrow outline—VRE detection and sample identification; solid red arrow—VRE detection and VRE concentration exceeding the PNEC and sample identification; red horizontal line—the PNEC for vancomycin (8000 ng/L).